WO2005052003A3 - Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis - Google Patents
Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis Download PDFInfo
- Publication number
- WO2005052003A3 WO2005052003A3 PCT/US2004/038660 US2004038660W WO2005052003A3 WO 2005052003 A3 WO2005052003 A3 WO 2005052003A3 US 2004038660 W US2004038660 W US 2004038660W WO 2005052003 A3 WO2005052003 A3 WO 2005052003A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- laminin
- metastasis
- chain
- antibodies
- tumor growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52389503P | 2003-11-20 | 2003-11-20 | |
US60/523,895 | 2003-11-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005052003A2 WO2005052003A2 (en) | 2005-06-09 |
WO2005052003A3 true WO2005052003A3 (en) | 2005-09-15 |
Family
ID=34632842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/038660 WO2005052003A2 (en) | 2003-11-20 | 2004-11-18 | Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005052003A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8545845B2 (en) | 2008-06-18 | 2013-10-01 | Karl Tryggvason | Antibodies against domains of laminin-332 |
EP2198884A1 (en) | 2008-12-18 | 2010-06-23 | Centre National de la Recherche Scientifique (CNRS) | Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004039401A2 (en) * | 2002-10-29 | 2004-05-13 | Sirpa Salo | Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis |
US20040120959A1 (en) * | 2001-01-08 | 2004-06-24 | Karl Tryggvason | Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis |
-
2004
- 2004-11-18 WO PCT/US2004/038660 patent/WO2005052003A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040120959A1 (en) * | 2001-01-08 | 2004-06-24 | Karl Tryggvason | Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis |
WO2004039401A2 (en) * | 2002-10-29 | 2004-05-13 | Sirpa Salo | Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis |
Non-Patent Citations (3)
Title |
---|
KOSHIKAWA NAOHIKO ET AL: "Overexpression of laminin gamma2 chain monomer in invading gastric carcinoma cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 21, 1 November 1999 (1999-11-01), pages 5596 - 5601, XP002214130, ISSN: 0008-5472 * |
SIRPA SALO ET AL.: "Laminin-5 promotes adhesion and migration of epithelial cells: identification of a migration-related element in the gamma2 chain gene (LAMC2) with activity in transgenic mice", MATRIX BIOLOGY, vol. 18, 1999, pages 197 - 210, XP002317649 * |
STOLTZFUS PATRICIA ET AL: "Laminin-5 gamma2 chain expression facilitates detection of invasive squamous cell carcinoma of the uterine cervix", INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, vol. 23, no. 3, July 2004 (2004-07-01), pages 215 - 222, XP002333471, ISSN: 0277-1691 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005052003A2 (en) | 2005-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL244803A0 (en) | Humanized anti-beta7 antibodies and uses therefore | |
TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
WO2004069152A3 (en) | Δ4,5 glycuronidase and uses thereof | |
PH12015500550A1 (en) | Anti-notch1 nrr antibodies and methods using same | |
IL214325A (en) | Anti-cmet antibody, composition comprising it and use thereof | |
WO2004080425A3 (en) | Polypeptide compounds for inhibiting angiogenesis and tumor growth | |
WO2005115431A3 (en) | Methods for inhibiting proteasome and heat shock protein 90 | |
WO2005009928A3 (en) | Preparation and use of alkylating agents | |
WO2004087073A3 (en) | Treatment of demyelinating conditions | |
TW200613308A (en) | Cyclobutanetetracarboxylate compound and preparation method thereof | |
AU2003297568A8 (en) | Compositions, methods, and kits for weight loss and inhibiting the loss of lean body mass | |
TW200621744A (en) | Mercaptoamides as histone deacetylase inhibitors | |
EP1551388A4 (en) | Compounds useful for the treatment of cancer, compositions thereof and methods therewith | |
UA83203C2 (en) | Thiazol-(bi)cycloalkyl-carboxanilides and their use for fighting against undesirable microorganisms | |
MXPA05005484A (en) | Method for enhancing the physico-chemical properties of bitumen compositions and novel bitumen compositions with enhanced properties and their uses. | |
WO2004045545A3 (en) | Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression | |
WO2005052003A3 (en) | Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis | |
WO2005073254A3 (en) | Methods for inhibiting squamous cell carcinoma using antibodies against laminin | |
WO2005120200A3 (en) | Amine compounds and inhibiting neurotransmitter reuptake | |
MXPA05009428A (en) | Compositions and methods for preventing and treating endotoxin-related diseases and conditions. | |
ZA200408272B (en) | Compositions for improving the flavor of alcoholicbeverage made from grape. | |
WO2004103289A3 (en) | Driverse thyroid hormone receptor antagonists and uses thereof | |
WO2004043400A3 (en) | Peptide deformylase activated prodrugs | |
WO2004039401A3 (en) | Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis | |
WO2004050834A3 (en) | GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |